Home/Filings/4/0001209191-17-013940
4//SEC Filing

Adamas Pharmaceuticals Inc 4

Accession 0001209191-17-013940

CIK 0001328143operating

Filed

Feb 22, 7:00 PM ET

Accepted

Feb 23, 5:38 PM ET

Size

9.8 KB

Accession

0001209191-17-013940

Insider Transaction Report

Form 4
Period: 2017-02-21
Went Gregory T
DirectorChief Executive Officer10% Owner
Transactions
  • Award

    Common Stock

    2017-02-21+23,125169,333 total
  • Award

    Stock Option (Right to Buy)

    2017-02-21+138,750138,750 total
    Exercise: $17.20Exp: 2027-02-20Common Stock (138,750 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    80,000
  • Common Stock

    (indirect: By Trust)
    80,000
  • Common Stock

    (indirect: By Trust)
    195,392
Footnotes (2)
  • [F1]The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2018, March 20, 2019, March 20, 2020 and March 20, 2021, subject to Reporting Person's Continuous Service as of each such date.
  • [F2]The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with April 1, 2017, subject to Reporting Person's Continuous Service as of each such date.

Issuer

Adamas Pharmaceuticals Inc

CIK 0001328143

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001328143

Filing Metadata

Form type
4
Filed
Feb 22, 7:00 PM ET
Accepted
Feb 23, 5:38 PM ET
Size
9.8 KB